Long-term success of heart transplantation is hindered by humoral and cell-mediated immune responses. We studied preexisting antibodies to cardiac self-antigens, myosin and vimentin, and exosomes induced by antibodies to self-antigens in eliciting immune responses to cardiac grafts. After syngeneic heterotopic murine heart transplantation, rabbit anti-myosin or normal rabbit immunoglobulin was administered at day 0 or 7.
| INTRODUCTION
Organ transplantation is a therapeutic option for patients with endstage organ disease. Chronic rejection is a major impediment to the long-term survival of heart allografts after heart transplantation (HTx) and results from a recurrent immune response to the transplanted organ, affecting mainly the arteries and capillaries. 1 During the rejection process, normal tissue architecture is replaced by fibrous scar tissue. 2 Cardiac allograft vasculopathy (CAV) is a feature of chronic rejection, characterized by occlusive narrowing of coronary vessels within the intramyocardial microvasculature. 3, 4 Studies have demonstrated that CAV develops in about 50% of transplant recipients within 7 years, 5 and the development of CAV can be either antigen dependent or antigen independent. Recent studies have demonstrated that autoimmune responses may play an important role in the pathogenesis of CAV. [6] [7] [8] Ab-mediated rejection can result in allograft dysfunction after HTx and is characterized by capillary injury, C4d deposition, and the presence of CD68 + cells in endomyocardial biopsy specimens.
Development of donor-specific Abs (DSAs) to mismatched donor HLA has also been reported to be involved in chronic rejection. 9, 10 A strong correlation exists between de novo development of DSAs and both acute and chronic cardiac allograft rejection. 9, [11] [12] [13] In addition, recent reports strongly support that acute and chronic rejection after transplantation of the heart, 14 lungs, 15 and kidneys 14, 16 may be associated with immune response to non-HLA antigens. Further, preexisting Abs to tissue-restricted self-antigens (SAgs) have been associated with primary graft dysfunction, de novo development of Abs to donor HLA, and increased risk of chronic rejection after human lung transplantation. 17 Preexisting Abs to angiotensin type II receptor have also been shown to lead to Ab-mediated rejection after human kidney transplantation. 18 Cardiac myosin (MYO) is an autologous contractile protein, an SAg that is recognized by both T and B cells during rejection. 19 Murine HTx models have shown that sensitization with MYO before transplantation can lead to accelerated rejection of not only allogeneic grafts but also syngeneic heart grafts. 19 Another tissue-specific SAg implicated in the development of CAV is the intermediate filament protein vimentin (VIM), which is found in cells of mesenchymal origin. 20 Recent studies have demonstrated that increased levels of Abs to MYO and VIM are significantly associated with the development of DSAs and CAV after HTx. 21 Recent findings indicate that exosomes may play a role in tissue rejection. Exosomes are vesicles that measure roughly 40-100 nm in diameter, originated by the endocytic pathway and released into body fluids with mRNA, cytosolic proteins, and micro-RNA (miRNA). [22] [23] [24] [25] Abs to SAgs can lead to exosome formation, and the role of Abs to SAgs in inducing graft rejection remains to be determined. The aims of this study were to determine the role of Abs to MYO in inducing exosomes and to define their role in graft failure after murine syngeneic HTx. We demonstrate that exosomes are induced after the administration of Abs to cardiac MYO and that the circulating exosomes express not only SAg MYO but also VIM and can result in the failure of heterotopically transplanted syngeneic hearts. Further immunization with exosomes containing cardiac SAgs can also result in graft failure.
| MATERIALS AND METHODS

| Mice
Six-to 12-week-old male C57BL/6 (H-2b) mice were obtained from
The Jackson Laboratory and housed in the animal care facility at Norton Thoracic Institute. These studies were approved by our institutional animal care committee. Five animals per group were used for all of the experiments.
| Heterotopic HTx
Syngeneic (C57BL/6-to-C57BL/6) heterotopic HTx was performed in the abdominal cavity, as previously described. 26 Briefly, the donor's ascending aorta and the pulmonary trunk from the heart graft were anastomosed end-to-side to the recipient's intrarenal abdominal aorta and inferior vena cava, respectively, using 10-0 sutures. Cold ischemic times were less than 30 minutes.
| Administration of rabbit anti-MYO Abs
Rabbit anti-MYO Abs was prepared by immunization of purified cardiac MYO (New England Peptide LLC, Gardner, MA). Anti-MYO IgG was purified using a Protein A column, according to manufacturer protocol (Sigma Aldrich, St Louis, MO). The titer of rabbit anti-MYO analyzed by ELISA was 1:64 000. Abs were tested for endotoxins (<1.67 EU/mg) by using the limulus amebocyte lysate assay. Purified rabbit anti-MYO IgG (200 μg/mL in 100 μL) was administrated intraperitoneally after syngeneic murine HTx on days 0 and 7. Failure of the transplanted organ was defined by cessation of a palpable heartbeat and was confirmed by histopathologic examination.
| Assessment of histologic changes
Cardiac grafts were obtained after the cessation of palpable beat (day 7) or from functioning syngeneic transplants (day 30) and were fixed with paraformaldehyde and embedded in paraffin. Then, 5-μm sections were stained with hematoxylin and eosin to assess histopathologic changes. 
| Detection of Abs to SAgs (MYO and VIM)
| ELISpot
The frequency of cells secreting SAg-specific interferon (IFN)γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-17 cytokines was determined by ELISpot as described previously. 17, 28 In brief, Abs to IFNγ, TNF-α, IL-17, and IL-10 (5 μg/mL) were coated in the 96-well plate and incubated at 4°C overnight (BD Biosciences, San Jose, CA). 
| Exosome isolation from serum via ultracentrifugation
Exosomes from sera were isolated by using the ultracentrifugation method. 29 Briefly, sera were centrifuged at 2000 g for 30 minutes
at 4°C and thereafter at 10 000 g for 30 minutes at 4°C to remove cells and cell debris. Sera were diluted with 1× PBS and centrifuged at 10 000 g for 90 minutes at 4°C. The pelleted exosomes were solubilized with 1× PBS and used for further analysis. Exosome protein concentration was quantified by using the Pierce bicinchoninic acid protein assay kit (ThermoFisher Scientific, Waltham, MA). Exosome purity was verified by exosome-specific marker CD63 by immunoblotting. 30 Exosomes were validated by using the sucrose cushion method as described by Gunasekaran et al 31 and by size determination (40-100 nm) with the use of transmission electron microscopy (TEM).
| Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting
Serum exosomes were resuspended in radioimmunoprecipitation assay buffer. Exosome proteins were diluted in 4× Laemmli buffer (Bio-Rad Laboratories, Hercules, CA) and incubated at 95°C for 5 minutes. Samples were loaded onto 10-12% precast polyacrylamide gel (Bio-Rad), and bands were electroblotted to a polyvinylidene fluoride membrane (Bio-Rad). For analysis of MYO and VIM, membranes were probed with Abs to MYO and VIM (Santa Cruz Biotechnology).
Membranes were probed with specific secondary Abs conjugated with horseradish peroxidase. Membranes were exposed to x-ray films to detect staining.
| Immunogold staining
For immunogold staining of exosomes, formvar carbon-coated copper grids were probed with mouse anti-CD63 Ab (1:100) or mouse anti-MYO or mouse anti-VIM (1:50) for 30 minutes, followed by specific secondary Ab conjugated to 18-nm colloidal gold (Jackson ImmunoResearch Laboratories). Grids were washed and stained with uranyl acetate, and staining was observed with the use of TEM (JEOL USA Inc, Peabody, MA).
| miRNA profiling
Exosomes were isolated from pooled sera (collected from 5 mice).
The mirVana miRNA isolation kit (Applied Biosystems, Foster City, CA) was used to isolate miRNA from exosomes. Isolated miRNA were subjected to the GeneChip miRNA array (ThermoFisher Scientific) for miRNA profiling. Partek Genomics Suite 6.6 software (St Louis, MO) was used to analyze differentially expressed exosomal miRNA. The heat map for miRNA in rejected and stable samples was generated by R statistics software.
| TaqMan miRNA real-time-polymerase chain reaction
Total RNA from sera exosomes was isolated by using the mirVana miRNA isolation kit (Applied Biosystems) and reverse-transcribed by using the TaqMan miRNA Reverse Transcription Kit (Applied Biosystems). Real-time-polymerase chain reaction (RT-PCR) was performed with the use of TaqMan miRNA assays as described by Xu et al. 
| Immunization of mice with exosomes
Exosomes were isolated from the sera of mice after cessation of heartbeat following HTx or from mice with stable syngeneic grafts.
Exosomes (100 μL of 100 μg/mL) were injected into mice subcutaneously with incomplete adjuvants on days 0, 3, and 7 after syngeneic HTx. Sera were collected on days 3, 7, and 15 and were used to measure Abs to SAgs. After cessation of the heartbeat, spleens were isolated for detecting SAgs specific to cellular immune responses and induced cytokines.
| Statistical analysis
Statistical data were expressed as mean ± SD. All the P values were calculated by using a 2-tailed t-test with GraphPad Prism 5. P < .05
was considered statistically significant.
| RESULTS
| Administration of Abs to cardiac MYO immediately after syngeneic HTx leads to graft failure
To determine the role of Abs to cardiac MYO in HTx, we performed syngeneic heterotopic HTx in C57BL/6 mice, and rabbit anti-cardiac MYO or normal rabbit sera (200 μg/mL of purified IgG) were administrated immediately after the transplantation (day 0). As shown in Figure 1 -A1, the administration of normal rabbit IgG had no effect on syngeneic heart grafts, and palpable heartbeats were noted until the time of death (30 days). In contrast, immunization with anti-MYO IgG administered to mice immediately after transplantation induced inflammatory cell infiltration and damage to cardiac myocytes, resulting in graft failure and cessation of heartbeat by day 7 (Figure 1-A2) . Therefore, Abs to SAgs present at the time of transplantation may activate an inflammatory cascade, leading to graft failure. Further, Abs administered on day 7 after syngeneic HTx had no effect on transplanted hearts, as these grafts remained functional up to 30 days after transplantation (Figure 1-A3 ). Anti-MYO administration had no effect on the native hearts, which showed normal architecture without any cellular infiltration. Morphometric analysis was used to quantitate cellular infiltration, which demonstrated an increased number of lymphocytes in rejected mice compared with controls (Table S1 ). Survival curve ( Figure 1B) showed that median survival of mice with anti-MYO on day 0 is day 7 and for other groups is day 30 when mice were killed with functioning hearts.
| Development of Abs to SAgs in mice injected with anti-MYO Abs
To 
| Cardiac SAgs MYO and VIM are detectable on the surfaces of exosomes
Exosomes isolated from mice following heartbeat cessation after administration of anti-MYO on day 0 and exosomes isolated from control mice (control or anti-MYO administered on day 7) were analyzed for the surface expression of SAgs by using immunogold TEM.
Exosomes were <100 nm in diameter and were stained specifically 
| Immunoregulatory miRNAs in exosomes
To investigate the potential contribution of serum-derived exosomic miRNA involved in the induction of inflammation that leads to heart graft failure, we identified the miRNA content of exosomes isolated from sera of mice with failed grafts (mice with anti-MYO on day 0) and from controls (normal IgG on day 0 mice and rabbit anti-MYO on day 
| Administration of exosomes from failed syngeneic grafts after the administration of anti-MYO-induced rejection of syngeneic cardiac grafts
To determine the immunogenicity of exosomes expressing SAgs, we administered exosomes containing SAgs, isolated from sera after the cessation of heartbeat induced by anti-MYO and compared these exosomes with those of the controls (normal or anti-MYO on day 7).
The results demonstrated that exosomes containing SAgs isolated from mice after cessation of heart function (ie, anti-MYO administered on day 0) induced cellular infiltration and myocyte damage to syngeneic heart grafts, resulting in the cessation of heartbeat on day 7 ( Figure 6A ). Quantification of infiltration showed the presence of a higher number of neutrophils with lymphocytes (data shown in Table S1 ).
Further, the addition of exosomes induced higher levels of Abs to cardiac SAgs MYO (12 μg/mL vs 6.5 µg/mL, P = .005) and VIM (7 μg/ mL vs 3.5 µg/mL, P = .003) compared with controls ( Figure 6B ). We also administered exosomes prepared from rejected animals on days 6 and 7 without adjuvant, which resulted in rejection of HTx by day 7, similar to the results obtained when anti-MYO was given immediately after heterotopic HTx (data not shown). To determine the mechanisms contributing to failure of syngeneic cardiac grafts after the administration of anti-MYO, we administered anti-MYO either immediately after transplantation (on day 0) or on day 7 after transplantation. In mice that received Abs to MYO on day 0, we found that the grafts stopped functioning on day 7. However, the grafts did not stop functioning when Abs to MYO was administered on day 7. In addition, we did not find any cellular infiltration or myocyte damage to the native heart. These results suggest that ischemia- proinflammatory cytokines with concomitant loss of peripheral regulation to SAgs.
| DISCUSSION
